Rx Rundown: Merck, Novo Nordisk, Viking Therapeutics and more
Check out this week’s medical marketing news, dealmaking and industry chatter.
Source: mmm-online.com
📰 Astrazeneca Ultomiris News
Astrazeneca Ultomiris News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Astrazeneca Ultomiris. Real-time updates on events, politics, business and more.
GlobalData : FDA approval of subcutaneous Vyvgart tackles one of the unmet needs in myasthenia gravis indication, says GlobalData
23 Jun, 2023 FDA approval of subcutaneous Vyvgart tackles one of the unmet needs in myasthenia gravis indication, says GlobalData Share Print page Posted in...
Source: marketscreener.com
BioBlast w/e 12 May 23
Korea Biomed has reported that Celltrion Healthcare has won bids to supply Vegzelma®, biosimilar to Genentech’s Avastin® (bevacizumab), in Italy and…
South Korea Emilia Romagna Comunidad Autonoma De Cataluna Bayer Regeneron Eylea Zion Pharma Innovent Biologics Eli Lilly
Source: lexology.com
AstraZeneca, Argenx Score Phase III Wins in Autoimmune Space
Two biologic therapeutic candidates have met their primary endpoints in phase III trials, including AstraZeneca’s Champion-NMOSD trial and Argenx’s Advance trial.
Seanj Pittock Argenx Vyvgart Astrazeneca Ultomiris Catherine Broome Mayo Neuroimmunology Laboratory Drug Administration
Source: biospace.com
Ultomiris of long-term clinical benefit in myasthenia gravis patients
New Ultomiris follow-up data shows sustained functional improvements in certain adults with generalised myasthenia gravis (gMG).
Gianluca Pirozzi Astrazeneca Ultomiris European Union Head Of Development Senior Vice President Astrazeneca Rare Disease
Source: europeanpharmaceuticalreview.com
Argenx's Vyvgart Offers a Substantial Advance Over Other Treatments for Generalized Myasthenia Gravis, Spherix Survey Suggests
/PRNewswire/ -- At the end of last year, argenxs Vyvgart (efgartigimod alfa-fcab) was approved by the FDA for the treatment of generalized myasthenia gravis...
Roche Genentech Roche Genentech Ocrevus Vyvgart Argenx Ultomiris Astrazeneca Astrazeneca Ultomiris Our Services
Source: prnewswire.com